Pancreatic safety of GLP-1-based therapeutic agents: Further insights from rodent studies?

Diabetologia

Volumn 56, Issue 9, 2013, Pages 1869-1872

  Holst, Jens Juul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alpha cells; Duct cellular pancreatic cancer; Incretins; Liraglutide; Pancreatitis

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; SITAGLIPTIN;

CELL PROLIFERATION; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INSULIN RESISTANCE; NONHUMAN; NOTE; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; RECEPTORS, GLUCAGON;

EID: 84881610740     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2984-z     Document Type: Note

References (37)

1. Ellenbroek JH, Töns HAM, Westerouen van Meeten MJA et al (2013) Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia. doi: 10.1007/s00125-013-2957-2
2. Sturis J, Gotfredsen CF, Romer J et al (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140:123-132
3. Bock T, Pakkenberg B, Buschard K (2003) The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 111:1117-1124
4. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43:104-108
5. Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
6. Valverde I, Villanueva Penacarrillo ML (1996) In vitro insulinomimetric effects of GLP-1 in liver, muscle and fat. Acta Physiol Scand 157:359-360
7. Toft-Nielsen M, Madsbad S, Holst JJ (1996) The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556
8. Orskov L, Holst JJ, Moller J et al (1996) GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232
9. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439
10. Moens K, Heimberg H, Flamez D et al (1996) Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45:257-261
11. Heller RS, Kieffer TJ, Habener JF (1997) Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46:785-791
12. 2+ channel-dependent exocytosis. Cell Metab 11:543-553
13. 2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46:792-800
14. Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB (2003) Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 5:330-335
15. de Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263-2270
16. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. doi: 10.2337/db12-1686
17. Nauck MA (2013) A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. doi: 10.2337/dc12-2504
18. Kahn SE (2013) Incretin therapy and islet pathology: a Time for Caution. Diabetes 62:2178-2180
19. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-7405
20. Malhotra R, Singh L, Eng J, Raufman JP (1992) Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regul Pept 41:149-156
21. Lando HM, Alattar M, Dua AP (2013) Elevated amylase and lipase levels in patients using glucagon-like peptide-1 receptor agonists or dipeptidyl- peptidase-4 inhibitors in the outpatient setting. Endocr Pract 18:472-477
22. Nyborg NC, Molck AM, Madsen LW, Knudsen LB (2012) The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 61:1243-1249
23. Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D (2013) No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab 15:417-426
24. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ (2009) Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58:2148-2161
25. Cohen D (2013) Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? Br Med J 346:1-9
26. Engel SS, Williams-Herman DE, Golm GT et al (2010) Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 64:984-990
27. Mari A, Sallas WM, He YL et al (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894
28. Williams AJ, Thrower SL, Sequeiros IM et al (2012) Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab 97:E2109-E2113
29. Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276
30. Bunck MC, Corner A, Eliasson B et al (2011) Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34:2041-2047
31. Grimelius L, Hultquist GT, Stenkvist B (1975) Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol 365:275-288
32. Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 36:933-942
33. Bagger JI, Knop FK, Holst JJ, Vilsboll T (2011) Glucagon receptor antagonism for the treatment of type 2 diabetes. Diabetes Obes Metab 13:965-971
34. Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438-1443
35. Longuet C, Robledo AM, Dean ED et al (2013) Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: evidence for a circulating alpha-cell growth factor. Diabetes 62:1196-1205
36. Brand CL, Jorgensen PN, Knigge U et al (1995) Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol 269:E469-E477
37. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC (2012) Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Krasn(G12D) mouse model. Diabetes 61:1250-1262